

**In the United States Patent and Trademark Office**

**Application for Patent for  
COLLECTING AND MANAGING CLINICAL INFORMATION**

**by**

**Joseph A. Leveque, M.D.  
Lori Dolan Frymark  
Douglas D. Lind, M.D.**

Shearman & Sterling  
599 Lexington Avenue  
New York, New York 10022  
(212) 848-4000

Atty. Docket No. 31949/2  
Express Mail Label EJ621326605US

NYDOCS04/298909

# COLLECTING AND MANAGING CLINICAL INFORMATION

## BACKGROUND

The present invention relates to a system for collecting, managing, analyzing and reporting information relating to clinical, economic and/or epidemiological outcomes.

It has been known to develop and manage databases containing clinical outcomes related to medical information collected from cancer patients. It has also been known to develop economic databases to compare treatment costs between certain diseases and between certain hospitals, on both the inpatient side and on the outpatient side, where the primary focus has been on physician professional services in the outpatient setting.

In addition, several other private and public institutions have been in the business of developing epidemiological databases. It has been known to develop a longitudinal database around coronary artery disease where a study was conducted over the course of many decades to track people who had a known risk for coronary artery disease. As time progressed, new risk factors were identified and incorporated into the database and the ultimate outcomes of those patients were tracked. Individual patients were tracked and information was recorded from the time the patient was diagnosed to the time the patient died. Additionally, all incidental complications were tracked and recorded, for example, such as whether or not they died from a complication related to their heart disease.

There are other cancer-related databases that are being developed either in the private sector or through private sponsorships. A pilot study is currently in progress for breast cancer and lymphoma to collect clinical and economic outcomes at numerous hospitals. It has been

known that the use of the data is primarily to evaluate the adherence to certain guidelines to determine if the effects on the quality of care.

Typically, information for such longitudinal medical studies similar to those mentioned above typically is gathered through written survey forms where people are either contacted on the phone, visit a doctor, and at the time of that visit or at the time that phone conversation the data was collected in a direct fashion using a written survey.

### **SUMMARY**

In general, in a first aspect, the invention features method for processing medical information which may include gathering longitudinal medical information of a patient and aggregating and anonymizing the longitudinal medical information into selected categories incident to a particular disease.

In general, in a second aspect, the invention features a method for processing medical information of a patient which may include gathering longitudinal medical information of patients from at least one hospital in order to determine phenotype information and communicating the longitudinal information in an aggregated and anonymized format to the at least one hospital.

In general, in a third aspect, the invention features a method for processing medical information which may include gathering longitudinal medical information of a patient and from at least one relative of the patient from at least one hospital where such longitudinal medical information is collected and managed and communicating the longitudinal medical information in an aggregated and anonymized format to at least one hospital.

In general, in a fourth aspect, the invention features a method for correlating longitudinal medical information of a patient afflicted with disease which may include gathering longitudinal

medical information of the patient afflicted with disease and from relatives of the patient from at least one hospital where such longitudinal medical information is collected, determining phenotype information from the gathered longitudinal information, and communicating the longitudinal information aggregated and anonymized to at least one hospital.

In general, in a fifth aspect, the invention features a method for correlating longitudinal medical information of at least one patient afflicted with disease which may include gathering longitudinal medical information from each one of at least one patient afflicted with disease and from relatives of each one of the at least one patient from at least one hospital where such longitudinal medical information is collected to determine phenotype information, anonymizing the longitudinal information, storing the longitudinal information on a database accessible to at least one hospital, and communicating the longitudinal information aggregated and anonymized to at least one hospital.

In general, in a sixth aspect, the invention features a method for processing longitudinal medical information of at least one patient afflicted with disease which may include collecting longitudinal medical information from each patient as each one progresses through a diagnostic, a treatment and a follow-up stage of the disease, anonymizing the longitudinal medical information, and storing the longitudinal information on a database accessible by at third party user.

In general, in a seventh aspect, the invention features a method for processing longitudinal medical information of at least one patient afflicted with disease which may include gathering longitudinal medical information from a medical institution where such longitudinal medical information may be collected and managed, aggregating the longitudinal medical

information, anonymizing the longitudinal medical information, and storing the longitudinal medical information in a database accessible by at least one hospital.

In general, in an eighth aspect, the invention features a method for processing longitudinal medical information of at least one patient afflicted with disease which may include gathering longitudinal medical information from at least one hospital where such longitudinal medical information is collected and managed, aggregating the longitudinal medical information, anonymizing the longitudinal information, determining phenotypic information from the longitudinal medical information, and storing both the longitudinal information and the phenotypic information in at least one database accessible by at least one hospital.

In general, in a ninth aspect, the invention features a method which may include gathering longitudinal medical information from at least one patient afflicted with disease and from relatives of each one of the at least one patient, and communicating the longitudinal information in an aggregated and anonymized format to at least one hospital.

In general, in a tenth aspect, the invention features a method for determining phenotype information which may include gathering longitudinal medical information of at least one patient from at least one hospital where such longitudinal medical information is collected, aggregating the longitudinal medical information, anonymizing the longitudinal medical information, comparing the longitudinal information gathered from each one of at least one patient with pre-determined genetic data ascertained from both each one of at least one patient and at least one relative of each one of at least one patient, determining a phenotypic expression of the comparison, and storing the longitudinal information and the phenotypic expression in a database accessible by at least one hospital.

In general, in an eleventh aspect, the invention features a method for determining a correlation between genetic predispositions and phenotype information in order to successfully treat disease which may include correlating longitudinal medical information gathered from at least one hospital where such longitudinal medical information is collected where the longitudinal information being collected from at least one patient having a disease and at least one relative of each one of the at least one patient, aggregating the longitudinal medical information, anonymizing the longitudinal medical information, and storing the longitudinal information in a database accessible by each one of the at least one hospital.

Preferred embodiments of the invention may include one or more of the following features. Particular embodiments of the invention may feature one or more of the following advantages including generating information such as disease susceptibility, severity, progression, quality of life, workforce participation, productivity and morbidity.

Particular embodiments of the invention may feature one or more of the following advantages including identifying genes that may predispose people to cancer whose pathways of action are associated with documented and previously unknown environmental carcinogens and lifestyle exposures, quantifying risk resulting from environmental carcinogens and lifestyle exposures, or integrating information on disease susceptibility and environmental carcinogens and lifestyle exposures in order to estimate cancer risks for individuals, families and populations.

In general, in a twelfth aspect, the invention features a method for doing business which may include providing computer hardware to a medical institution at less than market price, in return for access to patient data generated at the medical institution.

Particular embodiments of the invention may feature selling or offering for sale the patient data available in an anonymized form to customers outside the medical institution.

In general, in a thirteenth aspect, the invention features a method which may include aggregating patient data drawn from multiple incompatible databases into a single database in an anonymized form, and providing access to the single database to a user.

In general, in a fourteenth aspect, the invention features system for managing clinical information including a first database for storing patient data, a computer interconnected to the first database, where the computer is programmed to anonymize and aggregate the patient data, and a second database interconnected to the computer, where the second database for storing the anonymized and aggregated the patient data.

Particular embodiments of the invention may feature one or more of the following advantages including where the first database includes information in the group consisting of genetic profile, disease susceptibility, severity, and progression, where the second database includes information in the group consisting of quality of life, workforce participation, productivity and morbidity, where the computer may be programmed to identifying genes that may predispose people to cancer whose pathways of action are associated with documented and previously unknown environmental carcinogens and lifestyle exposures or where the computer is programmed to determine a phenotypic expression of the patient data.

In general, in a fifteenth aspect, the invention features a system for determining a phenotypic expression of a patient having a genetic predisposition for disease, which may include at least one hospital having a first database for storing local disease outcomes information, a vendor having a second database, where the second database may be interconnected to the first database, the second database for storing patient data collected from the at least one hospital, and a computer programmed to anonymize and aggregate the patient data, where the second database is accessible by third party users.

The above advantages and features are of representative embodiments only, and are presented only to assist in understanding the invention. It should be understood that they are not to be considered limitations on the invention as defined by the claims, or limitations on equivalents to the claims. Additional features and advantages of the invention will become apparent in the following description, from the drawings, and from the claims.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

In the drawings, which illustrate, in a non-limiting fashion, the best mode presently contemplated for carrying out the present invention:

FIG. 1 is a block diagram;

FIG. 2 is a flow chart;

FIGS. 3a-3e are flow charts of FIG. 2 in detail at various stages;

FIG. 4 is a flow chart of information flow;

FIGS. 5a-5e are flow charts of alternative embodiments of the system described in FIG 4;

and

FIGS. 6a-6c shows various forms used to collect medical information.

### **DESCRIPTION**

Generally, the present system may generate information related to disease susceptibility (risk factors), severity (morbidity) and progression; resource utilization (cost); quality of life (health status and well being); workforce participation and productivity; and mortality. The present system may also integrate a study of the distribution and causes of disease in human populations with cutting-edge genetic and related molecular technologies. The present system



may also develop a scale and migratable disease outcomes research and surveillance platform at an interface of genetics and epidemiology that can be applied toward:

- **Gene Identification** - The system may identify genes that may predispose people to cancer (cancer susceptibility genes) whose pathways of action are associated with documented and previously unknown environmental carcinogens and lifestyle exposures.
- **Risk Quantification** - The system may quantify risk resulting from certain types of exposures by studying genetically susceptible subgroups.
- **Information Integration** - The system may integrate information on genetic susceptibility and environmental exposures to estimate cancer risks for individuals, families and populations.
- **Advance Understanding** - The system may contribute to the design of new approaches to prevent, predict, diagnose and treat cancer based on an understanding of how genes modify and interact with environmental exposures.

Generating disease outcomes information that is powerful enough to examine the complex interactions of multiple genetic and environmental factors requires a comprehensive, interdisciplinary research infrastructure that is ideally situated and managed within patient care facilities. A research infrastructure and platform may be developed to generate disease outcomes information from the following activities:

- **Disease Outcomes and Surveillance Studies** - Disease outcomes and surveillance studies may be developed to assess the impact of novel predictive, preventive, diagnostic and therapeutic interventions on disease susceptibility, severity and progression; resource utilization; quality of life; workforce participation and productivity; and mortality.
- **High-Risk Patient Studies** - High-risk patient studies may be developed to evaluate individuals at high risk of cancer as they utilize novel predictive, preventive, diagnostic and therapeutic interventions.
- **Environmental Exposure Studies** - Environmental exposure studies may be developed to assess complex cancer-related environmental exposures.
- **Family-Based Studies** - Family-based studies may be developed to quantify inherited cancer risk and investigate genetic and environmental modifiers of risk and identify potential candidates for novel predictive, preventive, diagnostic and therapeutic interventions.

- **Population-Based Studies** - Population-based studies may be developed to identify clinically valid subpopulations of cancer patients who are unresponsive to conventional therapies and candidates for novel predictive, preventive, diagnostic and therapeutic interventions.

Referring now to FIG. 1, working with one or more hospitals or other academic medical hospitals **10**, a data processing vendor **40** may provide computer services to collect, manage, analyze and report clinical, economic and epidemiological data and outcomes information (collectively, "patient data") collected from diagnosis to death. Hospital **10** may be one or more medical institutions such as an academic medical, secondary or tertiary care hospital, clinic, or any other medical facility that gathers medical or medically-related information on a patient. Vendor **40** may collect patient data from hospital **10** into a local outcomes database **14**, and make database **14** available to hospital **10**. Patient data may also be collected directly from patients without the intervention of hospitals **10**. Patient data may be collected by mail in information forms, telephone surveys, or electronically, via the Internet, electronic mail or other telematic transmission. Alternatively, vendor **40** may install database **14** on site at hospital **10** to be used along side of, or in replacement of, the hospital's pre-existing patient data information legacy systems **210**, **213**, **217** (discussed below). Vendor **40** may also establish physical operations onsite at hospital **10**; for instance, vendor **40** may install a complete computer system including a database, a central processing unit, and multiple terminals at hospital **10**, possibly at no cost or with a subsidy to hospital **10**, and make that computer system available for the computing needs of hospital **10**. Vendor **40** may aggregate together databases **14** from several hospitals **10** to form a network of databases. Alternatively, vendor **40** may create a data warehouse **150** which can be accessible by hospital **10**. With appropriate privacy safeguards, hospitals **10** may obtain non-anonymized access to data warehouse **150** to obtain a patient's comprehensive history across

all hospitals **10**, which may benefit the hospitals' research programs, and may allow improved patient care.

Vendor **40** may also make an anonymized version **1002** of database **14** or data warehouse **150** available to users **72-80** external to hospital **10** ("anonymized data" have had their patient identity encoded or encrypted so that the data cannot be traced to a specific patient, but the data relating to the same specific patient may be identified, and are distinguished from the data of other patients). Vendor **40** may charge a commercial access fee for access by external users **72-80**.

Patient data stored in local outcomes database **14** or data warehouse **150** may include information relating to genetic profile, susceptibility, progression, severity of disease, the resources utilized to treat the disease, quality of life, ability to participate in the workforce and survival. Database **14** may also provide hospital **10** with an integrated longitudinal view of individual patients, correlating information from a number of different physicians, hospital departments, disease states, treatments and outcomes, rather than providing views fractured by department or disease state. Such an integrated and correlated local outcomes database **14** may facilitate analysis of a patient's genotype (the genetic makeup of an individual) and phenotype information, along with information relating to the patient's relatives. Such analysis may provide an understanding of why genetically similar patients express the same disease differently. Collecting phenotypic information and linking that information to genotypic information may provide insights into the role that a person's genotype plays in disease contraction, treatment and outcome.

Vendor **40** may provide products, technology, and services provided to academic medical center **10** under an outcomes research and disease surveillance capability management agreement

20. A local outcomes research and disease surveillance information technology may be used to create and populate the local outcomes database **14**, in which is collected information on disease susceptibility, severity, progression, resource utilization, quality of life, work force participation and productivity and survival. Local outcomes database **14** may be implemented at the site of the hospital **10**.

After development of database **14**, vendor **40** may create a comprehensive data warehouse **150** (see FIG. 4e) where disease specific outcomes information from other hospitals **10** may also be stored. These other hospitals **10** may independently operate within the system and store, manage and analyze the collected information via an electronic connection such as the internet.

Referring again to FIG. 1, vendor **40** may aggregate and anonymize patient data from affiliated network of hospitals **10** who utilize a networked database system. The patient data may be stored and managed within data warehouse **150** that is a research and product development asset of vendor **40**. Vendor **40** may have a marketing and business development aspect where it can mine data warehouse **150** for the purpose of discerning clinical, market, economic, professional practice and other types of insights **62, 64, 66, 68, 70** (hereinafter **62 et seq.**). These insights **62 et. seq.** may be extracted from data warehouse **150** by an insight extraction application **41** developed in insight developments **42**. Insights **62 et. seq.** may be of commercial value and offered to potential customers.

Disease outcomes applications **24** may be developed by vendor **40** and provides to hospital **10** for accessing database **14**, data warehouse **150**, or insight developments **42**. Reports **151, 153, 157** (see FIGS. 4e and 6a-6c) may be issued in response to queries and searches of database **14**, data warehouse **150**, or insight developments **42** which can be published or accessed

by the affiliated network of partners. These reports may be provided to pharmaceutical companies, third party payers, or perhaps governmental entities (box **50**), which can apply the information as necessary.

Alternatively, vendor **40** may market and develop research capabilities incident to disease outcomes **44** to pharmaceutical companies, third party payers, or to governmental entities, to provide particular studies of interest either of commercial interest or a public interest.

Examples of possible participating pharmaceutical companies might include Astra-Zeneca, Merck, Bristol-Myers Squibb, Glaxo, Pfizer, and Smith-Kline Beecham. Examples of possible biotech companies might include Amgen, Biogen, and Genentech, and examples of possible genomic companies might include Millennium, Celera, Curagen, Human Genome Sciences and Myriad. Such companies may be potential customers for data warehouse **150** for information and may become affiliated research sites along with hospitals **10** to conduct studies on their particular products.

Vendor **40** may also develop and/or provide disease management applications, programs and services **56**. Vendor **40**, after processing the gathered longitudinal information into aggregated and anonymized categories, may develop programs and services to take advantage of the insights **62** et. seq. gained from insight developments **42**. Vendor **40** may develop products and services for accessing data warehouse **150** that may be commercially valuable to the pharmaceutical industry **72**. Such programs may reveal clinical insights (Box **62**) into clinical care of a patient **101** and how that care may change due to an intervention made as a result of knowledge gained through analyzing data warehouse **150**. Other areas of interest may include market insights (Boxes **62**, **64**) into where a drug is being used, the quantity, the number of patients in those markets, and where potential markets might exist. Price and risk insights

(Boxes 66, 68) provide a better understanding of the value of a certain product for treating a certain, particular patient in a given market, which can help companies price (Boxes 66, 68) their product or help providers 78 enter into risk contracts with payers. Insights 62 et. seq. into how fast physicians adopt these drugs and how patients are using them may be ascertained from the gathered information in data warehouse 150.

Insights 62 et. seq. may be valuable to the pharmaceutical industry 72 and companies now designated as E-health companies 74 (or electronic health companies) that are interested in developing content for websites. Insights 70 may also be desirable to insurance companies 76, who may be interested in understanding how to better manage diseases and how to pay for diseases in a more efficient way. Care providers 78 may use insights 62 et. seq. to provide better care of patients. Patients 80 themselves may look at the gathered information in data warehouse 150 in order to increase their understanding about their own disease.

Referring to table 1, another technology developed for the system may include a data mining application 41 which may be used to query data warehouse 150 for the specific insights 62 et. seq. In addition to insight extraction applications that may provide clinical insights and market insights (Boxes 66, 68), there may be reports (see FIG. 5) derived via data mining application 41 queries of data warehouse 150. Other insight 62 et. seq. services may include care insights, risk and price insights, adoption insights, compliance insights and specific custom disease management applications, programs and services used to develop disease-specific patient management guidelines, critical event consultation, premium and case rate pricing and economic risk sharing models, promoting and tracking physician adoption and patient compliance with prescribed interventions.

**Table 1: Summary of Possible Vendor Products, Technology and Services**

<b>Product or Service</b>	<b>Description</b>	<b>Potential Targeted Customers</b>
<b>Database 14</b>	Local outcomes database may be used to collect information on disease susceptibility, severity, progression, resource utilization, quality of life, workforce participation and survival. Local outcomes database 14 may be implemented at academic medical centers.	Provider Pharmaceuticals
<b>Data Warehouse 150</b>	Global comprehensive data warehouse where disease-specific outcomes information is may be stored, managed and analyzed. Data warehouse 150 may be linked via the Internet to Database 14.	Pharmaceuticals Payers Providers E-Health
<b>Data Mining Software Application 41</b>	Data mining software applications may be used to query Data Warehouse 150 for specific insights.	Pharmaceuticals Payers E-Health
<b>Reports 151, 153, 157</b> Clinical Insights Market Insights	Standing reports derived from queries of Data Warehouse 150 to publish disease-specific clinical and market insights.	Pharmaceuticals E-Health Payers Providers
<b>Insight Developments 62 et. seq.</b> Care Insights Risk/Price Insights Adoption Insights Compliance Insights	Custom disease management applications, programs and services may be used to develop disease-specific patient management guidelines and critical event consultation; premium and case rate pricing and economic risk-sharing models; and promoting and tracking physician adoption and patient compliance with prescribed interventions.	Providers Payers Pharmaceuticals
<b>Electronic Communications Services 60</b> Insight Communications DiseaseOutcomes.com	Internet electronic communication services may be used to disseminate reports, programs and services to customers and patients.	Pharmaceuticals E-Health Patients



Insights **62** et. seq. developed from mining data warehouse **150**, may be communicated either to the customer segment directly or to a network of care providers affiliated with vendor **40**. The network of affiliated care providers may gather these insights **62** et. seq. and act upon them in a timely fashion so that new insights that can have impact on patient care. Additionally, knowledge gained from insights **62** et. seq. can be incorporated in the treatment regimes at a much faster pace than they would through dissemination of information at medical meetings or in journals where the lag time for publishing results is much longer.

Electronic communication services **60** may be implemented to provide internet based access **25** to data warehouse **150** through an insight communications website portal. One embodiment may be observed at the url: [www.diseaseoutcomes.com](http://www.diseaseoutcomes.com). The website portal may provide internet electronic communication services **60** to disseminate reports **151, 153, 157**, programs and services **56** to vendors **40**, hospitals **10**, customers **72, 74, 76**, and patients **101**.

Referring now to FIG. 2, a new patient **101** (for example, having a suspected breast cancer) enters a diagnostic phase **105** where tests are conducted **107** (see FIG. 4a). To confirm a diagnosis, the information is collected, for example, on pathology of a tumor after it has been biopsied. Imaging studies may also be conducted to localize the tumor, and lab studies may be conducted to further define the extent of the disease. In the course of the diagnostic phase many resources may be utilized including those of academic hospitals accessed via the local outcomes database **14**. Vendor **40** may have access to many databases including those of hospital **10** where patient **101** is physically located, i.e., where patient **101** is being managed. For instance, an institutional database **210** (IDB) located at hospital **10** may include information on medical history, physical examination results, laboratory results, imaging results, drugs that have been prescribed, disease staging, tumor staging, and clinical status. Vendor **40** may have access to

IDB **210** of hospital where patient **101** is located for real time access to the elements of information on pathology, imaging, lab and resource utilization stored within local databases. Alternatively, insight database **62** et. seq. may be integrated with IDB **210**.

Once a patient **101** has been diagnosed with a disease, patient **101** may be provided with information regarding the system and how it works. Patient **101** may be given the choice to opt out of the system or to allow free access to the information related to their disease and how it affects him or her personally. Patient **101** may be advised of his/her privacy rights and that all the information gathered will be anonymized when added to the system or provided outside hospital **10**. With the permission of patient **101**, and after a confidentiality agreement is executed by patient **101**, the patient's information is added local outcomes database **14**.

When patient **101** has been diagnosed he or she enters an evaluation phase **110**. During the evaluation phase **110** one or both of two disease profiles may be developed: a first disease profile **113** for the diagnosed patient **101**; and a second disease profile **115** for a relative of the patient with the confirmed disease **117**. Each disease profile **113**, **115** includes information relating to medical history, comorbidities, which are other diseases that a patient has that are either related or unrelated to their primary disease, a risk factor profile and blood samples. For a patient with cancer, typical information gathered on comorbidities may include information on types of conditions that are affecting the patient such as hypertension.

Disease profile **113** may be developed during the period of time between diagnosis and treatment. Disease profile **113** may include a baseline profile that includes a computer database record and a biological sample record regarding patient **101**. The baseline profile can also include information on disease susceptibility, which can be derived from medical history. The source of the medical history and the co-morbidity information may be the IDB **210** or the local

disease management system **213** (DMS) (see FIG. 3b). A risk factor profile may also be developed that may include information on the social history of patient **101**. For example whether patient **101** smokes cigarettes, uses alcohol or drugs, or has other social habits that may have contributed to the disease. The risk factor profile may also take into account a patient's environmental exposures, including the patient's work history, possible exposure to toxins or to carcinogens such as asbestos. Exposure to known carcinogens and other toxic substances may be inventoried at this time and assessed as a risk factor. The baseline profile may also include a blood sample information which is collected, catalogued, stored and may be made available for further genetic analysis, if necessary, to come to a further or better understanding of the genetic makeup of the patient and how that genetic makeup may have been mutated by environmental factors that resulted in the disease.

Disease profile **113** of patient **101** may contain additional information known as baseline severity. Baseline severity may include clinical status information and performance status information. Clinical status information may include information such as disease stage, menopausal status and prior treatment status. One possible measurement of performance status is the well known Karnofsky performance status assessment, which is a validated instrument used to evaluate a patient's ability to practice activities of daily living while they have the disease. The Karnofsky assessment uses a scale graded between 0% to 100%, where 100% represents a patient having a disease but no deficiencies from such disease, and 0% represents the patient being dead. The rate of disability increases as the score decreases. The baseline outcomes generated may be applied to prospective surveys on quality of life and workforce participation in disease profile **113** (see FIG. 3b).

Referring to FIG. 3b, a disease profile **115** may be created for each of one or more blood relatives of patient **101**. As conducted with the patient **101**, longitudinal medical information may be collected from the relatives of patient **101**. Such information collected may include medical histories, co-morbidities, risk factor profiles, and a blood sample for further genetic analysis. Similar to patient **101**, the relative of the patient may be advised of the privacy rights at issue and a confidentiality agreement may be entered.

Referring to FIG. 3c, upon completion of evaluation phase **110**, patient **101** enters the treatment phase **120**. During treatment phase **120**, patient **101** may receive a number of different drugs that may be cycled over a period of thirty days. Disease profiles **113**, **115** may be updated any number of times during treatment phase **120** until patient **101** is either in remission or the disease has progressed to the point where patient **101** is no longer eligible for treatment. The information collected during treatment phase **120** may include information on the severity of progression, clinical status and performance status as previously defined. The source of that information can be the IDB **210** or its DMS **213**. Local outcomes database **14** and data warehouse **150** (see FIG. 3c) may be compiled **127** with the information from disease profiles **113**, **115** including susceptibility, severity, progression, and with on-going outcomes information such as resource use, quality of life, and work force participation.

Clinical status information in disease profiles **113**, **115** may include complications of toxicity as it relates to treatment status. NCI applies a common toxicity scale for certain complications that fall into hematological complications, which are complications of the blood that may be related to low blood cell counts. These hematological complications may include low white cell counts (leukopenia), paucity of neutrophils (neutropenia), low red blood cell counts (anemia), or low platelet counts (thrombocytopenia). There are infectious complications,

which include fever, localized infection or sepsis, which is an infection within the blood that's due to doses of chemotherapy that cause low white blood cell counts, hence limiting the ability of patient **101** to fight infection. Alternatively, there may be neurological, endocrine, cardiac or other types of constitutional complications that fall under the treatment status, which may be collected at this time.

There may also be information collected on clinical response (see FIG. 6a). Categories of clinical response may include complete response, partial response or no response. A complete response includes the case where there is an absence of disease after treatment. A partial response includes, for example, that the size of the tumor has decreased in size during treatment but has not been completely eliminated. Information can also be collected from patients **101** that did not respond at all, which indicates that the tumor did not shrink in size or it increased in size during the treatment process. Overall response is the average of complete and partial responses.

Referring to FIG. 3d, following the end of the treatment phase **120** patient **101** may enter a follow-up phase **130**. Follow up phase **130** may include an aftercare period, a period after which patient **101** may be in remission, until patient **101** experiences a relapse, or until patient **101** no longer requires monitoring. During follow-up phase **130**, disease profile **131** for patient **101** may be amended to include information regarding long-term outcomes data. Blood samples may also be collected at various points during this period of time. Additional risk factors may also be determined for example, during the remission phase, if there is any exposure to substances that might be cause a relapse or cause exposure to another tumor. Long-term outcomes are may be collected again such as resource issues, quality of life, workforce participation and, ultimately, survival. This information may be added to databases **14**, **150** as collected.

Vendor **40** may continue to monitor both patient **101** with a confirmed disease and his or her relatives. Additionally, during this period disease profiles **113**, **115** for both patient **101** and his or her relatives may be updated to track patient's **101** and his or her relatives' respective clinical status, performance status, and clinical response. For the relatives of patient **101**, additional information may be collected such as medical history, co-morbidities, risk factors, and blood samples. Each of the relatives of patient **101** may be monitored for an extended period of time, usually on a regular basis, perhaps once or twice a year until patient **101** dies or develops acute disease and falls into a different category.

Referring to FIG. 3e, data warehouse **150** can be a single location where all gathered information is stored and aggregated. Reports can be created using the information from data warehouse **150** including academic reports **151**, business reports **153**, and clinical reports **157**.

The phenotypic information stored in data warehouse **150** may assist in expressing a patient's **101** genetic makeup in a negative manner that may be indicative of contributory factors relating to patient's **101** contraction of the disease. In addition, the phenotypic information can be matched to a blood sample that contains genetic data about patient **101** and his or her relatives. This matching of phenotypic and genetic information may create a phenotypic expression indicative of a particular disease that may become an asset of both vendor **40** and hospital **10**.

Referring to FIG. 4, information may be gathered by routine collection of data by the doctors and nurses from a patient input onto standard patient data forms (discussed below and see FIG.S 6a-6c). Through an electronic interchange the patient data may be stored in any one or a combination of legacy systems **210**, **213**, **217** within hospital **10**, which may be, for example, Memorial Sloan Kettering Cancer Center. Legacy systems **210**, **213**, **217** of hospital **10** may

include institutional database (IDB) **210**, disease management system (DMS) **213**, and an order management system (OMS) **217**, where OMS **217** tracks the resources that are used to care for patients **101**. IDB **210** that may store clinical information and DMS **213** may store clinical information under various defined protocols incident to patient **101** given his or her disease and the stage thereof.

Both vendor **40** and hospital **10** may contribute newly collected information to legacy systems **210, 213, 217**. Items of information for which vendor **40** needs to develop programs may be designated from the legacy systems **210, 213, 217**. Vendor **40** may also collect information that may not necessarily be derived from legacy systems **210, 213, 217** in order to supplement the legacy systems **210, 213, 217** information resource. Information flows and technology developed by vendor **40** may be directly integrated into legacy systems **210, 213, 217** of hospital **10**. Alternatively, vendor **40** and hospital **10** may use local outcomes database **14** to store patient data that may be integrated directly with legacy systems **210, 213, 217** and data warehouse **150**.

Vendor **40** may also supplement data warehouse **150** by implementing an evolving technology known as XML, (Extensible Markup Language) **220** to tag, search, transfer and index the gathered information to a common language. Legacy systems **210, 213, 217** of hospital **10** may be built on one or a variety of common software database systems such as Oracle, Cybase, or DB2. By using XML technology to tag the information within legacy systems **210, 213, 217**, vendor **40** may aggregate information from disparate data sources into a common format. From that common format, the data may be translated into and communicated into whichever language is chosen as the format for data reporting.

From the common format, vendor **40** may use a relational database **225** to manage, analyze, and visualize **230** the information via various commonplace software tools and newly created applications. Once the information is visualized **230** it can be reported in the form of academic reports **151** such as publications and research documents that can be presented at conferences and the like. Alternatively, the information can be presented in business reports **153** used to facilitate payer and network development negotiations. Clinical reports **157** may also be used to provide the information, which may continually improve the clinical care being provided at the hospital.

Academic report **151** can be used to describe, for example, the characteristics of patient **101** who is treated with a particular drug and the clinical response is being evaluated. For example, characteristic information collected from patient **101** would be demographic information such as age, pathologic information related to their tumor size, or the histology of the tumor. For example, in the case of breast cancer, the histology would be designated as infiltrating ductal, lobular, modular, tubular or other designations of the site of metastases.

Reports **157** may include information such as the stage of the disease, any prior surgical and non-surgical treatment, chemotherapy or radiation therapy. Reports **157** may include treatment status, which may describe a level of complications or toxicity, and the performance status. Still another outcome that may be tracked is the time to progression or when the treatment actually failed. All of the information may be considered and compared as it relates to complete response, partial response or overall response.

Referring to FIGS. 5a-5e, hospital **10** can be, for example, an NCI cancer center that may have an Outcomes Research/Disease Surveillance (ORDS) Program **45** established. In addition to legacy systems **210**, **213**, and **217**, hospital **10** may include a tumor registry **216** where



information related to various types of tumors may be stored. Using ORDS program **45** hospital **10** may develop academic applications **152**, business applications **154**, and clinical applications **158**. Academic applications **152** can include various publications **160** and business applications **154** can facilitate Payer and Network Development **162**, which in combination can provide Enhanced Patient Volume **165**.

Referring to FIG. 5b vendor **40** may be integrated with hospital **10** and customer segments **72** via direct linking of data warehouse **150**, local outcomes data warehouse **14**, and clinical outcomes research **22**. Customer segments **72** may include pharmaceutical, biotechnology, genomics or other third party business. Customer segments **72** may also include applications **35** such as drug design, discovery and marketing divisions, patient management insights, and e-health content (FIG 5c). In one embodiment vendor **40** may use data mining application **41** to mine data warehouse **150** and apply the information gained therefrom to insights developments **42**. Insights **62** et seq. may be directly provided to the customer segments including pharmaceuticals **72**, e-health companies **74**, insurance companies **76**, care providers **76**, and patients **101** (FIG. 5d). Care providers/payers may access data warehouse **150** via web based Internet connections **25**.

Referring now to FIGS. 6a-6c, hospital **10** may be able to define a particular response level. Similar characteristics may be used to define a response level of patient **101**, whether it be complete or partial, which can be represented in five elements about clinical outcomes. Vendor **40** may collect and report information regarding clinical outcomes, resource utilization, quality of life, workforce participation, and ultimately, survival. Vendor **40** may also add information to comparisons of response rates known as Quality Adjusted Life Years Saved or QUALYS. QUALYS is a calculation which uses quality of life and resource utilization to determine a

measure of the value of a certain procedure or treatment in economic terms. QUALYS allows hospital **10** and patient **101** to determine the cost of healthcare, the likelihood and timing of survival, and the incident quality of life.

Workforce participation may be determined by surveying the patient's occupation, the salary level, time lost from work and the economic loss related to both loss of earnings or paying taxes as calculated. Also determined may be the length of time it takes for a patient to get back to work and the level of productivity they are working at in conjunction with disease management.

Referring to FIG. 6c, a clinical report **151** may incorporate risk and prognostic factors or the susceptibility to the disease as another way of evaluating a patient's response. For example, in the risk prognostic factors category, it is possible to define genetic susceptibility, which could be any number of genes associated with the cancer that the user is evaluating. Clinical report **151** may also include a factor a prior history of exposure, including environmental exposures that may have mutated these genes or may have been responsible for the actual creation of the cancer.

Sequencing genetic information may also be ascertained by providing access to the information collected from patient **101** and the relatives of patient **101**. Certain genes responsible for certain tumors can be located and the resulting tumors may be more responsive based on the genetic makeup to certain treatments than they would be responsive to other ones. For example, some of those genetic genes may relate to severity which translates to, gene A is responsible for tumor A and tumor A is responsive to treatment A. In this case, treatment B, C or D would not, be used because treatment A is known to work best. On the other hand, gene B, which is responsible for tumor B, may be present and may not have a responsive treatment B for it. Treatment A, C or D or a combination of those may be used in this case to get control of the

tumor. However, if the disease is not responsive to any of those treatments the disease, itself, would be more severe and progress more rapidly.

As a result, tailor made treatments can be provided to certain tumors that have a genetic basis, and a clinical report **151** form can be generated (see FIG. 6c) which can include the actual genetic susceptibility for which patient **101** may be at risk. Incident to that risk, a determination can be made relating to some patients with a particular gene in that whether when treated with treatment A patient **101** has more complete responses than when treated with treatment B. This determination may result in an increased knowledge base regarding how to effectuate complete responses when certain genes are present and because of the particular gene present the resulting tumor is more responsive to treatment A. Therefore, in this scenario, treatments B, C or D will not be used anymore.

Although the present invention has been described in detail with respect to certain embodiments and examples, variations and modifications exist which are within the scope of present invention as defined in the following claims.